PureTech Founded Entity Akili Reports Investigator-Initiated Study Results of AKL-T01 for Systemic Lupus Erythematosus
Shots:
- The unblinded study evaluated AKL-T01 in 60 patients aged 18-65yr. with SLE. The study was conducted by the National Jewish Health & University of Colorado School of Medicine Departments of Neurology, Psychiatry & Rheumatology
- The study showed an improvement in motor speed & executive flexibility/sequencing over the control group & provided further validation of Akili’s technology platform to improve select cognitive impairments across different indications. The results were published in the journal Lupus
- The results also provide the preliminary evidence of EVO monitor to provide a rapid mobile assessment of cognitive function & improvement in EVO monitor with no differences in other neuropsychological, behavioural, or health outcomes
Ref: Bussinesswire | Image: PureTech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
